Sionna Therapeutics, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Sionna Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -20.37, a change of -10.25 year-over-year.
- Sionna Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -21.09, a change of -14.14 year-over-year.
- Sionna Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -24.52.
- Sionna Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -18.53.
- Sionna Therapeutics, Inc. pe ratio for fiscal 2026 was -20.37.
- Sionna Therapeutics, Inc. pe ratio for fiscal 2025 was -24.52.
- Available history
- 2025-03-31 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |